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Background/Aims: The incidence of Hepatitis B has significantly declined since the introduction of an HBV vaccination 
program. The aim of this study was to investigate recent clinical features of acute viral hepatitis B (AVH-B) in Korea. 
Methods:  A total of 2241 patients with acute viral hepatitis were enrolled and their data were collected from nine 
medical-centers between January 2006 and December 2009. Results: One hundred nineteen (5.3%) of the 2241 were 
diagnosed as AVH-B. Among 78 patients with AVH-B whose data were analyzed, 50 were male, and the mean age was 
38.6 years. In an initial test, mean AST, ALT and total-bilirubin levels were 1296.2 IU/L, 2109.6 IU/L and 9.3 mg/dl, 
respectively. Positivity frequencies for HBeAg and anti-HBe were 55.1% and 67.9%, respectively, and the mean HBV DNA 
level was 5.2 log10 copies/ml. The mean length of hospitalization was 11.6 days. During follow-up, AST, ALT and total 
bilirubin levels were normalized or near-normalized in all patients without serious complications. Sixty-three of 66 (95.4%) 
patients showed HBsAg loss and 37 (56.1%) patients showed HBsAg seroconversion. Only 3 patients (4.5%) showed 
persistent hepatitis B viremia. There was no case of death or liver transplantation. Nine patients (11.3%) had received 
anti-viral agents and their clinical outcomes were not significantly different from those of patients treated without antiviral 
agents. Conclusions: The prevalence of AVH-B among acute hepatitis patients is relatively low in Korea. AVH-B infection 
can be cured without complications in almost all patients, regardless of antiviral treatment.  (Korean J Hepatol 
2011;17:307-312)
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INTRODUCTION
The incidence of acute viral hepatitis B (AVH-B) in the 
United States has declined steadily since the late 1980s. The 
reduction in hepatitis B virus (HBV) incidence in the US 
may be attributed to effective vaccination programs as well 
as universal precautions for needle use and in healthcare in 
general.
1 In Korea, an endemic area of HBV, the positivity of 
hepatitis B surface antigen (HBsAg) also decreased from 8% 
to 3.7%, since routine HBV vaccination program were 
introduced.
2 Several single-center studies showed that the 
etiology of acute viral hepatitis in Korea has been changing.
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Cases of AVH-B as the etiologic agent in acute viral 
hepatitis declined in the most recent decade.
3 Most primary 
infections of HBV are self-limited with clearance of virus 
and development of immunity. However, an estimated 3% to 
5% of adults and up to 95% of children develop chronic 
HBV infection.
5 AVH-B can be symptomatic or asymptomatic. 
In asymptomatic cases, biochemical abnormalities such as 
elevations of aminotransferase levels are usually undetected 
unless a routine check-up is performed.
6 In symptomatic 
cases, prodromal symptoms include general malaise, anorexia, 
nausea, vomiting and fever, which may last for several days 
to weeks.
6 Right upper quadrant discomfort or flu-like 
symptoms may also present. The patient may then be icteric 
or unicteric.
6 Approximately 1% of persons with AVH-B 
develop acute liver failure.
7 Although the epidemiology has 
changed, changes in the clinical courses of AVH-B have not 
been reported in Korea. Therefore, the aim of this study was 
to analyze data for prevalence and demographic and clinical 
characteristics of AVH-B in Korea.
PATIENTS AND METHODS
Study population
In this investigator-initiated cohort study, 2241 adult 
patients were diagnosed with acute viral hepatitis from 
January 2007 and December 2009 in nine medical centers in 
Korea. Of the 2241, 119 (5.3%) were diagnosed with AVH-B. 
Among them, 78 patients whose data could be investigated 
were included in this study and analyzed retrospectively. 
The diagnosis of AVH-B was based on HBsAg positivity 
and/or anti-HBc IgM positivity with acute onset of symptoms 
including general weakness, abdominal pain, nausea, 
vomiting and jaundice, etc. No patient had a family history 
of hepatitis B. Laboratory test results that supported the 
diagnosis of AVH-B were elevated serum alanine aminotran-
sferase (ALT) and total bilirubin. None of the patients had a 
previous history of liver disease or reported any other causes 
of liver injury, such as alcohol or drugs. Patients with 
diagnoses of chronic hepatitis, HBV carrier, liver cirrhosis, 
gastric and esophageal varices, or liver cancer were excluded 
because such cases were considered to be chronic HBV 
infections. The study protocol was approved by the Institutional 
Review Board of each hospital and was conducted in 
accordance with the guidelines of the Declaration of Helsinki. 
Laboratory and clinical assessments
Serum ALT levels were measured at baseline, 12 months 
and final follow-up. HBV serology, including serum 
hepatitis B surface antigen (HBsAg), antibody to hepatitis B 
surface antigen (anti-HBs), hepatitis B e antigen (HBeAg) 
and antibody to hepatitis B e antigen (anti-HBe), was 
checked at baseline, 12 months and final follow-up. Serum 
HBV DNA levels were also assessed using the COBAS 
Amplicor PCR assay, which has a lower limit of detection of 
300 copies/mL (Roche Molecular Systems, Branchburg, NJ, 
USA). Rates of patients with ALT normalization, HBsAg 
serologic loss, HBsAg seroconversion and persistent HBV 
viremia were investigated at final follow-up. Incidence rates 
of complications, in-hospital mortality and length of stay 
were also investigated. Accepted criteria for defining 
clinical and serologic recovery from AVH-B are clearance of 
circulating HBsAg and appearance of anti-HBs, with 
normalization of serum aminotransferase levels. We analyzed 
clinical profiles of groups treated with antiviral agents 
compared with those of groups treated without antiviral 
agents.
Statistical analysis
HBV DNA levels were logarithmically transformed for 
analysis. Continuous variables were expressed as the mean± 
standard deviation (SD) and categorical variables as absolute 
and relative frequencies. The χ
2 test was used to analyze 
categorical variables such as gender and hepatitis serology 
including HBsAg, anti-HBs, HBeAg, and anti-HBe. 
Comparisons of continuous variables, such as age, serum 
HBV DNA level, and serum ALT level, were analyzed using 
a t-test. P-values less than 0.05 were considered statistically 
significant. SPSS version 17.0 was used for all statistical 
analysis (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the study population
A total of 2241 patients were diagnosed with acute viral 
hepatitis, and 119 (5.3%) of them were diagnosed with 
AVH-B (Fig. 1). Among the 119 AVH-B patients, 78 whose 
data could be investigated were enrolled. The baseline 
characteristics of the patients are shown in Table 1. The 
mean age of patients was 38.6 years and the highest rate Hye Jin Choi, et al. Acute hepatitis B in Korea  309
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Figure 1. Etiology distribution of acute viral hepatitis.
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Figure 2. Age distribution of acute viral hepatitis B.
Table 1. Baseline characteristics of patients
Characteristics n=78
Age, years  38.6±8.1
Male, n (%) 50 (64.1%)
Laboratory data
  Peak AST (IU/L) 1,296.2±883.7
  Peak ALT (IU/L)  2,109.6±1,235.8
  Peak total bilirubin (mg/dL)  9.3±6.8
  Prothrombin time (INR)  0.8±2.2
  Albumin (g/dL)  3.7±0.5
Serology
  HBsAg positive, n (%)  78 (100%)
  Anti-HBs positive, n (%)  10 (12.7%)
  IgM anti-HBc positive, n (%)  78 (100%)
  HBeAg positive, n (%)  43 (55.1%)
  Anti-HBe positive, n (%)  53 (67.9%)
  HBV DNA (log10 copies/mL)  5.2±1.1
AST, aspartate transaminase; ALT, alanine aminotransferase; 
HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis
B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, 
antibody to hepatitis B e antigen; anti-HBc, antibodies against 
the core antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic
acid.
corresponds to the group aged 30-39 years (Fig. 2). Thirty-one 
(40%) of 78 patients were more than 40 years old.
Clinical, biochemical and virologic profiles at the 
onset of AVH-B
All patients were HBsAg positive and IgM anti-HBc 
positive at presentation. Ten patients were anti-HBs positive. 
Forty three (55.1%) patients were HBeAg positive and 53 
(67.9%) patients were anti-HBe positive. The peak ALT 
levels ranged from 52 to 5477 IU/L, and the peak total 
bilirubin levels ranged from 0.8 to 33.8 mg/dL. The mean 
peak HBV DNA level were 5.2 log10 copies/mL and peak 
HBV DNA levels ranged from undetectable to 8.2 log10 
copies/mL (Table 1). Mean duration of hospitalization was 
11.6 days. 
Clinical, biochemical, and serologic profiles at 
follow-up
Seventy four patients were examined for clinical and 
serologic recovery (Table 2). Mean duration of follow-up 
was 9.6 months. At the final follow-up, serum ALT levels 
were within normal limits in 66 (89%) of the 74 patients. 
Sixty six of the 74 patients were examined for serologic 
markers for HBV. Sixty three (95.4%) of the 66 patients 
showed serologic loss of HBsAg, and 36 (54.5%) of the 66 
patients showed seroconversion of HBsAg. After final 
follow-up, 3 (4.5%) out of the 66 patients showed persistent 
hepatitis B viremia (Table 3). Three patients had follow-up 
for 9 to 18 months. They all showed normalization of serum 
ALT levels but persistent viremia. Symptoms related to 
AVH-B improved in all patients. There was no case of 
progression to fulminant hepatitis, death or liver trans-
plantation. 
Antiviral treatments and clinical courses
Nine (11.5%) patients among the 74 patients tested for 
serologic markers during the follow-ups had received antiviral 
agents (lamivudine for 3, entecavir for 4, and clevudine 
for 2). The mean duration of treatment was 10.3 months. At 
final follow-up, all patients showed normalization of ALT 
levels. Only 7 were examined for HBV serologic marker at 310  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 3. Characteristics of patients with persistent HBV viremia at final follow-up
Sex
/age
Initial laboratory data
Antiviral 
agent
Final follow-up data
HBsAg/ 
anti-HBs
HBeAg/ 
anti-HBe
HBV DNA
(log10 copies/mL)
ALT
(IU/L)
Duration
(months)
HBsAg/ 
anti-HBs
HBeAg/
anti-HBe
HBV DNA
(log10 copies/mL)
ALT
(IU/L)
M/39 +/+ -/+ 4.4   552 No 15 +/- -/+ 4.0 14
M/42 +/- -/+ 8.3 1,329 No   9 +/- -/+ 1.9 11
F/22 +/- +/- 3.9 2,111 No   9 +/- -/+ 2.6 10
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; Anti-HBs, antibody to hepatitis B surface antigen; HBeAg, 
hepatitis B e antigen; Anti-HBe, antibody to hepatitis B e antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid.
Table 2. Characteristics of patients at final follow-up
Characteristics Data
Duration of follow-up (months, mean±SD)
Biochemistry
  ALT (IU/L, mean±SD)
  ALT normalization, n (%) 
Serology
  HBsAg loss, n (%) 
  HBsAg seroconversion, n (%) 
  HBsAg positive, n (%) 
  HBeAg loss, n (%) 
  HBeAg seroconversion, n (%) 
  Undetectable HBV DNA, n (%) 
9.6±8.3
24.1±31.1
66/74 (89.0%)
63/66 (95.4%)
36/66 (54.5%)
3/66 (4.5%)
11/12 (91.6%)
10/11 (90.9%)
39/42 (92.8%)
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen;
anti-HBs, HBeAg, hepatitis B e antigen; anti-HBe, antibody 
to hepatitis B e antigen; HBV, hepatitis B virus; DNA, deoxyri-
bonucleic acid.
final follow-up and all showed HBsAg serologic loss. Four 
(57.1%) showed seroconversion of HBsAg. Sixty five 
patients were not treated with antiviral agents. Fifty five 
(94.8%) of 58 were examined for HBV serologic markers at 
final follow-up and showed HBsAg serologic loss. Thirty 
two (55.1%) of the 58 patients showed HBsAg seroconversion 
(Table 4). HBV clearance rates were not significantly 
different between the groups with and without antiviral 
treatment.
DISCUSSION
This study showed that the prevalence of AVH-B among 
acute viral hepatitis patients is relatively low, and that after 
the introduction of the HBV vaccination program in Korea 
the age group most susceptible to AVH-B had changed from 
people aged 10-29 years to people aged 30-39 years. 
Worldwide, two billion people have been infected with 
hepatitis B virus infection; 360 million have a chronic 
infection; 600,000 die each year from HBV-related liver 
disease or hepatocellular carcinoma.
8 Universal hepatitis B 
vaccination for all infants, which was introduced in the early 
1980s,  is now widely accepted as a fundamental strategy to 
protect the general public from this potentially severe 
disease.
8 Systemic immunization is the most cost-effective 
tool in preventing the spread of HBV infection.
9 A study 
conducted in Taiwan showed that since the introduction of 
the infant HBV immunization program in 1984, the prevalence 
rates of HBV infection in children under age 15 were 
reduced from 9.8% in 1984 to 1.3% in 1991.
10 In Korea, 
vaccination against HBV has been provided for infants born 
to mothers with HBV since 1983. Before the introduction of 
the HBV vaccination program, approximately 8% of the 
general Korean population tested positive for HBsAg.
11 The 
rate of HBsAg carriage in the general population had 
decreased to 3.7% by 2007. 
The majority of acute hepatitis B cases in the early 1980s 
occurred in people aged 10-29 years.
12 The decline in the 
incidence of acute hepatitis B after the introduction of the 
HBV vaccination program was more striking in adults aged 
10-29 years; these are individuals who were born after the 
introduction of HBV vaccination.
12 The incidence of acute 
hepatitis B has been changing in the early 2000s: it was 
highest among adults aged 30-39 years, who were born 
before the introduction of the HBV vaccination program.
4,12 
In this multicenter study, the mean age of patients was 38.6 
years and the highest rate corresponds to the group aged 
30-39 years. The age distribution of acute hepatitis B in our 
study was similar to that of a recent report by Yim et al.
4 
Therefore, unvaccinated and uninfected adults may be 
vulnerable to AVH-B and require catch-up vaccination to 
protect against HBV infection. 
Approximately 5% of all acute HBV infections progress 
to chronic infection, and the risk of progression from an Hye Jin Choi, et al. Acute hepatitis B in Korea  311
Table 4. Clinial features of two groups based on the presence or absence of the treatment using an antiviral agent 
Characteristics Treated without antiviral agent (n=65) Treated with antiviral agent (n=9) P
Age (years, mean±SD) 38.4±9.5 43.4±12.5 0.152
Male, n (%) 41 (64.0%) 6 (66.7%) 0.879
Initial laboratory data
  ALT (IU/L)  2,047.8±1,228.3 2635.4±946.2 0.173
  HBV DNA (log10  copies/mL) 6.7±7.4 6.6±7.9 0.904
  HBeAg positive, n (%) 33 (51.6%) 6 (66.7%) 0.671
  Anti-HBe positive, n (%) 45 (70.3%) 5 (55.6%) 0.448
Final laboratory data
  ALT (IU/L)  24.5±33.3 21.4±11.1 0.785
  ALT normalization, n (%) 57 (89.1%) 8 (88.9%) 0.988
  HBsAg loss, n (%)  55/58 (94.8%) 7/7 (100%) 0.433
  HBsAg seroconversion, n (%)  32/58 (55.1%) 4/7 (57.1%) 0.741
  Undetectable HBV DNA, n (%) 35/38 (92.1%) 4/4 (100%) 0.710
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to hepatitis 
B e antigen; anti-HBc, antibodies against the core antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid.
acute to chronic phase is inversely proportional to age.
13 In 
the acute phase of HBV infection, the manifestations range 
from subclinical hepatitis to symptomatic hepatitis requiring 
hospitalization. The most serious form of presentation of 
acute hepatitis is fulminant hepatic failure with a fatality rate 
of 70%.
14 One study on the incidence of fulminant hepatitis 
in acute viral hepatitis B patients showed the incidence of 
fulminant hepatitis was 6.0%.
15 In this study, the symptoms 
of AVH-B improved in all patients, and there was no case of 
progression to fulminant hepatitis, death, and liver trans-
plantation. Patients of tertiary hospitals were enrolled in this 
study and there was the possibility of including severe 
AVH-B cases, but the prognosis of enrolled patients was 
good.
In primary infection, HBsAg becomes detectable after 4 
to 10 weeks of incubation, followed by the presence of 
antibodies against the core antigen (anti-HBc) in IgM during 
the early period.
16 Viremia is well established by the time 
HBsAg is detected. Once this response has commenced, 
viral titers in blood and liver begin to drop. HBsAg is the 
first marker to appear in the blood. HBeAg may appear early 
but is cleared rapidly. HBsAg is cleared and its antibody, 
anti-HBs, appears within 6 months of disease onset in most 
cases. The outcome of acute hepatitis B is usually good with 
complete recovery from the liver damage and seroconversion 
to anti-HBs, which represents a long-term protection for 
HBV infection.
6 However, when persistent infection becomes 
established, serology markers like HBeAg, anti-HBe and 
anti-HBs can be positive or negative except HBsAg and 
anti-HBc IgG remain positive.
4  Yuki et al
17 showed that 
occult HBV infection persists in the liver and is accompanied 
by abnormal liver histology for a decade after complete 
clinical recovery from acute self-limited hepatitis B. In the 
present study, 63 (95.4%) of 66 patients showed serologic 
loss of HBsAg and 36 (54.5%) of 66 patients showed 
seroconversion of HBsAg. After final follow-up, 3 (4.5%) of 
66 patients showed persistent hepatitis B viremia. The rate 
of chronicity of AVH-B in the present study was similar to 
that in a previous report.
17
Uncomplicated, self-limited acute HBV requires no 
specific treatment. Some data have indicated a possible role 
for lamivudine treatment of selected patients with severe or 
fulminant acute HBV infection. Kumar, et al showed that 
though lamivudine causes a greater decrease in levels of 
HBV DNA, it does not cause significantly greater biochemical 
and clinical improvement as compared to placebo in patients 
with acute hepatitis B.
18 In another study, early treatment 
with lamivudine led to a greater decrease in HBV DNA 
levels, better clinical improvement and lower mortality in 
patients with severe acute hepatitis B.
19 In our study, we 312  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
compared HBsAg seroconversion rates, serum HBV DNA- 
negative rate, biochemical indicators, the incidence of liver 
failure and mortality between one group treated with 
antiviral agents and the other group without antiviral agents. 
The clinical outcomes between the two groups were not 
significantly different. One reason for the lack of significant 
difference could be that no patient suffered from persistent 
hepatitis B viremia in the group treated with antiviral agent. 
Limitations of our study include a small number of subjects 
and the retrospective design. Therefore, further evidence for 
antiviral agents in acute hepatitis B and fulminant hepatitis 
is required.
In conclusion, in this multi-center study, the prevalence of 
AVH-B among acute viral hepatitis patients is relatively low 
in Korea. The prognosis of patients with AVH-B is good in 
the majority of enrolled patients. However, some patients 
progress to a chronic state regardless of antiviral treatment. 
Catch-up HBV vaccinations in adult population may be 
required to protect against HBV infection in Korea.
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